Cargando…

Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire

INTRODUCTION: The use of patient reported outcome measures to support routine inflammatory bowel disease (IBD) care is not widespread and suggests that existing questionnaires lack relevance to day-to-day decisions or are too cumbersome to administer. We developed a simple, generic tool for capturin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bodger, Keith, Ormerod, Clare, Shackcloth, Daniela, Harrison, Melanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078750/ https://www.ncbi.nlm.nih.gov/pubmed/24107590 http://dx.doi.org/10.1136/gutjnl-2013-305600

Ejemplares similares

Fungal microbiota dysbiosis in IBD
por: Sokol, Harry, et al.
Publicado: (2017)

Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD
por: Selinger, Christian Philipp, et al.
Publicado: (2021)

A blood-based prognostic biomarker in IBD
por: Biasci, Daniele, et al.
Publicado: (2019)

Preclinical IBD: One more piece of the puzzle
por: Agrawal, Manasi, et al.
Publicado: (2023)

Modulation of cytokine patterns and microbiome during pregnancy in IBD
por: van der Giessen, Janine, et al.
Publicado: (2020)

Surfing the web as a patient with IBD: New horizons
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2023)

Life in lockdown: experiences of patients with IBD during COVID-19
por: Harris, Richard James, et al.
Publicado: (2020)

IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
por: Jones, Gareth-Rhys, et al.
Publicado: (2019)

BSG 2024 IBD guidelines protocol (standard operating procedures)
por: Gordon, Morris, et al.
Publicado: (2023)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD
por: Soendergaard, Christoffer, et al.
Publicado: (2018)

Current smoking habits in British IBD patients in the age of e-cigarettes
por: Chong, Chui, et al.
Publicado: (2019)

Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands
por: de Bock, Ellen, et al.
Publicado: (2021)

Whole exome sequencing analyses reveal gene–microbiota interactions in the context of IBD
por: Hu, Shixian, et al.
Publicado: (2021)

HLA-DR(hi) and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBD
por: Linton, Ludvig, et al.
Publicado: (2012)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD
por: Lee, Thomas, et al.
Publicado: (2017)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic
por: Bonsack, Olivier, et al.
Publicado: (2023)

Assessment of patients' understanding of inflammatory bowel diseases: Development and validation of a questionnaire
por: Ostromohov, Gaiana, et al.
Publicado: (2021)

Effectiveness of disease-specific cognitive–behavioural therapy on depression, anxiety, quality of life and the clinical course of disease in adolescents with inflammatory bowel disease: study protocol of a multicentre randomised controlled trial (HAPPY-IBD)
por: van den Brink, Gertrude, et al.
Publicado: (2016)

Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study
por: Dragoni, Gabriele, et al.
Publicado: (2023)

Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
por: Gaujoux, Renaud, et al.
Publicado: (2019)

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
por: Reinisch, Walter, et al.
Publicado: (2013)

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)

Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational study—CAPITAL (Cohort and Practice for IBD total management in Kyoto-Shiga Links) study I
por: Yoshino, Takuya, et al.
Publicado: (2016)

Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo‐controlled multicentre trial
por: Münch, Andreas, et al.
Publicado: (2021)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Crohn’s disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial
por: Raman, Maitreyi, et al.
Publicado: (2022)

Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism
por: Oancea, I, et al.
Publicado: (2017)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis
por: Weisel, Kathy, et al.
Publicado: (2021)

Sample‐size estimation is not reported in 24% of randomised controlled trials of inflammatory bowel disease: A systematic review
por: Iheozor‐Ejiofor, Zipporah, et al.
Publicado: (2021)

IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells
por: Ullrich, Karen Anne-Marie, et al.
Publicado: (2023)

Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation
por: Allocca, Mariangela, et al.
Publicado: (2021)

Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial
por: Münch, Andreas, et al.
Publicado: (2016)

Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse
por: Robinson, A, et al.
Publicado: (2013)

Epithelial RAC1-dependent cytoskeleton dynamics controls cell mechanics, cell shedding and barrier integrity in intestinal inflammation
por: Martínez-Sánchez, Luz del Carmen, et al.
Publicado: (2023)

Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ar9db5008884tc93dq2nm8uis4